Can IG-SRT be considered a first-line treatment for non-melanoma skin cancer?

Yes, indeed. In the past, surgery (especially Mohs surgery for certain cases) was often considered the only “first-line” standard. However, recent studies and clinical guidelines have elevated IG-SRT to a first-line option for basal and squamous cell skin cancers. Research published in 2022 and 2023 confirmed that image-guided SRT can be as safe and effective as Mohs, leading experts to conclude that IG-SRT should be given equal consideration as a standard-of-care treatment alongside surgery. What this means is that if you are diagnosed with an early-stage non-melanoma skin cancer, your dermatologist may offer you either Mohs surgery or IG-SRT as primary treatment choices, depending on your situation and preferences. Everyone deserves a surgery-free option, and IG-SRT is now recognized as an effective primary treatment, not just a backup or last resort.